盐酸阿考替胺在中国上市了吗？

As of early February 2024, it has not been listed in China.

Acotiamide hydrochloride is a new type of drug and the world's first approved treatment for functional dyspepsia (FD). Since its launch in Japan in 2013, acotiamide hydrochloride has attracted widespread attention from all walks of life around the world.

About acotiamide hydrochloride

Acotiamide is a new gastric motility drug, a muscarinic receptor antagonist and a cholinesterase inhibitor, which can significantly improve the symptoms of FD patients. The drug was initiated by Japan's Zari Shinyaku Co., Ltd. and jointly developed with Japan's Astellas Pharmaceutical Company. It was finally approved in Japan in March 2013, with the registered name Acofide, and was launched in Japan in June 2013, becoming the world's first drug for the treatment of FD diagnosed according to Rome III standards.

The role of acotiamide hydrochloride

Acotiamide not only has a good effect on promoting gastric motility and enhances gastric fundus relaxation, but can also improve gastric accommodation disorders to significantly reduce the early fullness and distension of FD patients. At present, Japan has conducted a number of clinical studies on acotiamide, such as breath test, ultrasound test and TQT test, etc., which have proved that this product can significantly improve the symptoms of FD, is highly safe, can still maintain the improvement effect after discontinuation of the drug, and is not prone to the formation of drug resistance after repeated administration.

It should be noted that the specific efficacy and safety of drugs may vary due to individual differences. For patients who use acotiamide to treat FD, they should follow the doctor's instructions, treat according to the correct dosage and usage, and have regular follow-up visits to evaluate the efficacy and side effects. If you have any discomfort or questions, you should consult your doctor promptly.

The efficacy of acotiamide hydrochloride

Acotiamide alone can treat FD, and combined treatment with other drugs has also shown good efficacy.

1. Single drug

The study by Yamawaki et al. [1] included 81 patients with FD, of which 35 One case was treated with acotiamide monotherapy, 28 cases were treated with acotiamide combined with rabeprazole, and 18 cases were treated with rabeprazole alone. All patients were followed up for 4 weeks after 4 weeks of treatment. The results showed that compared with the rabeprazole monotherapy group, both the acotiamide monotherapy group and the acotiamide combined with rabeprazole treatment group had better treatment satisfaction. Impaired gastric emptying was significantly improved in both groups, and the symptoms of upper abdominal pain syndrome (such as abdominal pain) in the combined treatment group were also significantly improved.

2. Combined medication

Hojo et al. found that when acotiamide combined with famotidine and acotiamide monotherapy were used to treat FD patients, the symptoms of postprandial discomfort syndrome and upper abdominal pain syndrome were significantly improved in both groups. The difference between the groups was not statistically significant. However, the proportion of patients in the combined treatment group whose upper abdominal pain syndrome symptom score decreased by more than 50% was significantly more than that in the acotiamide monotherapy group at each time point. The difference between the two groups was most obvious at 2 weeks of treatment. This suggests that acotiamide combined with proton pump inhibitor (PPI) treatment is more effective for patients with upper abdominal pain syndrome and can effectively improve symptoms.

The price of acotiamide hydrochloride

It is understood that the specification of acotiamide hydrochloride is 100mg*100 tablets, and the reference price range is between 360 and 450$.

As of early February 2024, acotiamide hydrochloride has not been launched in China. If patients want to buy acotiamide hydrochloride, they can go abroad by themselves, or find domestic and overseas medical service institutions to help them purchase acotiamide, saving worry and effort.

References

[1] Liu Yu, Hu Lianghao, Li Zhaoshen. Research progress of acotiamide in the treatment of functional dyspepsia [J]. International Journal of Gastroenterology, 2021, 41(01): 23-27.

Hot article recommendations: